Clinical Trial Update: Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001) [Phase 1]

View source ↗

Summary

Phase 1 single ascending dose study of MK-1092 in healthy participants and in individuals with Type 1 and Type 2 diabetes completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-1092

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED | Results posted: 2019-11-15